nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—kidney cancer—muscle cancer	0.364	1	CtDrD
Sorafenib—KIT—muscle cancer	0.229	1	CbGaD
Sorafenib—RALBP1—Vincristine—muscle cancer	0.0778	0.299	CbGbCtD
Sorafenib—RALBP1—Doxorubicin—muscle cancer	0.0486	0.187	CbGbCtD
Sorafenib—UGT1A1—Etoposide—muscle cancer	0.0123	0.0472	CbGbCtD
Sorafenib—ABCG2—Dactinomycin—muscle cancer	0.012	0.046	CbGbCtD
Sorafenib—ABCC4—Methotrexate—muscle cancer	0.00831	0.0319	CbGbCtD
Sorafenib—ABCC2—Vincristine—muscle cancer	0.00816	0.0314	CbGbCtD
Sorafenib—ABCC2—Etoposide—muscle cancer	0.00748	0.0287	CbGbCtD
Sorafenib—ABCG2—Vincristine—muscle cancer	0.00738	0.0283	CbGbCtD
Sorafenib—ABCG2—Etoposide—muscle cancer	0.00676	0.026	CbGbCtD
Sorafenib—CYP1A2—Dacarbazine—muscle cancer	0.0057	0.0219	CbGbCtD
Sorafenib—CYP3A7—Vincristine—muscle cancer	0.00545	0.0209	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.00545	0.0209	CbGbCtD
Sorafenib—ABCC2—Doxorubicin—muscle cancer	0.0051	0.0196	CbGbCtD
Sorafenib—ABCC2—Methotrexate—muscle cancer	0.00494	0.019	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—muscle cancer	0.00461	0.0177	CbGbCtD
Sorafenib—ABCG2—Methotrexate—muscle cancer	0.00447	0.0172	CbGbCtD
Sorafenib—ABCB1—Dactinomycin—muscle cancer	0.00432	0.0166	CbGbCtD
Sorafenib—CYP3A5—Vincristine—muscle cancer	0.00409	0.0157	CbGbCtD
Sorafenib—CYP3A5—Etoposide—muscle cancer	0.00375	0.0144	CbGbCtD
Sorafenib—CYP2C8—Etoposide—muscle cancer	0.0036	0.0138	CbGbCtD
Sorafenib—CYP2B6—Doxorubicin—muscle cancer	0.00324	0.0125	CbGbCtD
Sorafenib—CYP1A2—Etoposide—muscle cancer	0.00279	0.0107	CbGbCtD
Sorafenib—ABCB1—Vincristine—muscle cancer	0.00266	0.0102	CbGbCtD
Sorafenib—ABCB1—Etoposide—muscle cancer	0.00244	0.00937	CbGbCtD
Sorafenib—Regorafenib—KIT—muscle cancer	0.00196	1	CrCbGaD
Sorafenib—ABCB1—Doxorubicin—muscle cancer	0.00166	0.00639	CbGbCtD
Sorafenib—ABCB1—Methotrexate—muscle cancer	0.00161	0.00619	CbGbCtD
Sorafenib—CYP3A4—Vincristine—muscle cancer	0.00159	0.00612	CbGbCtD
Sorafenib—CYP2D6—Doxorubicin—muscle cancer	0.00157	0.00602	CbGbCtD
Sorafenib—CYP3A4—Etoposide—muscle cancer	0.00146	0.00561	CbGbCtD
Sorafenib—CYP3A4—Doxorubicin—muscle cancer	0.000997	0.00383	CbGbCtD
Sorafenib—KDR—hindlimb—muscle cancer	0.00097	0.0216	CbGeAlD
Sorafenib—MUSK—tendon—muscle cancer	0.000888	0.0198	CbGeAlD
Sorafenib—KDR—appendage—muscle cancer	0.000832	0.0186	CbGeAlD
Sorafenib—MUSK—testis—muscle cancer	0.000736	0.0164	CbGeAlD
Sorafenib—CDKL3—testis—muscle cancer	0.000656	0.0146	CbGeAlD
Sorafenib—CDKL2—head—muscle cancer	0.000621	0.0138	CbGeAlD
Sorafenib—CDKL2—testis—muscle cancer	0.0006	0.0134	CbGeAlD
Sorafenib—MAPK15—head—muscle cancer	0.000559	0.0125	CbGeAlD
Sorafenib—MAPK15—testis—muscle cancer	0.00054	0.012	CbGeAlD
Sorafenib—CDK7—renal system—muscle cancer	0.000487	0.0109	CbGeAlD
Sorafenib—CDK7—Idarubicin—Doxorubicin—muscle cancer	0.000428	0.333	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—muscle cancer	0.000428	0.333	CbGdCrCtD
Sorafenib—CDK7—Epirubicin—Doxorubicin—muscle cancer	0.000428	0.333	CbGdCrCtD
Sorafenib—FLT4—embryo—muscle cancer	0.000421	0.00938	CbGeAlD
Sorafenib—HIPK3—renal system—muscle cancer	0.000412	0.0092	CbGeAlD
Sorafenib—TIE1—smooth muscle tissue—muscle cancer	0.0004	0.00893	CbGeAlD
Sorafenib—TAOK2—tendon—muscle cancer	0.000377	0.00842	CbGeAlD
Sorafenib—AURKC—tendon—muscle cancer	0.000374	0.00835	CbGeAlD
Sorafenib—RET—embryo—muscle cancer	0.000371	0.00828	CbGeAlD
Sorafenib—HIPK3—cardiac atrium—muscle cancer	0.000369	0.00823	CbGeAlD
Sorafenib—HIPK4—testis—muscle cancer	0.000363	0.0081	CbGeAlD
Sorafenib—TAOK2—vagina—muscle cancer	0.00035	0.00781	CbGeAlD
Sorafenib—TIE1—cardiac atrium—muscle cancer	0.000345	0.0077	CbGeAlD
Sorafenib—MAPK11—head—muscle cancer	0.000331	0.00739	CbGeAlD
Sorafenib—ZAK—tendon—muscle cancer	0.000329	0.00733	CbGeAlD
Sorafenib—FLT1—embryo—muscle cancer	0.000327	0.00729	CbGeAlD
Sorafenib—CDK7—head—muscle cancer	0.000326	0.00727	CbGeAlD
Sorafenib—RAF1—embryo—muscle cancer	0.000325	0.00725	CbGeAlD
Sorafenib—UGT1A9—renal system—muscle cancer	0.000323	0.0072	CbGeAlD
Sorafenib—HIPK3—tendon—muscle cancer	0.000322	0.00718	CbGeAlD
Sorafenib—AURKC—head—muscle cancer	0.000321	0.00716	CbGeAlD
Sorafenib—MAPK11—testis—muscle cancer	0.00032	0.00714	CbGeAlD
Sorafenib—CDK7—testis—muscle cancer	0.000315	0.00703	CbGeAlD
Sorafenib—TAOK2—testis—muscle cancer	0.000313	0.00697	CbGeAlD
Sorafenib—HIPK3—bone marrow—muscle cancer	0.000312	0.00695	CbGeAlD
Sorafenib—AURKC—testis—muscle cancer	0.00031	0.00692	CbGeAlD
Sorafenib—MAP3K7—smooth muscle tissue—muscle cancer	0.000309	0.00689	CbGeAlD
Sorafenib—PDGFRA—embryo—muscle cancer	0.000306	0.00684	CbGeAlD
Sorafenib—ZAK—vagina—muscle cancer	0.000305	0.00681	CbGeAlD
Sorafenib—MKNK2—smooth muscle tissue—muscle cancer	0.000299	0.00668	CbGeAlD
Sorafenib—HIPK3—vagina—muscle cancer	0.000299	0.00666	CbGeAlD
Sorafenib—EPHA6—head—muscle cancer	0.000297	0.00663	CbGeAlD
Sorafenib—BRAF—tendon—muscle cancer	0.000288	0.00643	CbGeAlD
Sorafenib—MKNK2—renal system—muscle cancer	0.000288	0.00643	CbGeAlD
Sorafenib—EPHA6—testis—muscle cancer	0.000287	0.00641	CbGeAlD
Sorafenib—ZAK—head—muscle cancer	0.000282	0.00629	CbGeAlD
Sorafenib—FGFR1—cardiac atrium—muscle cancer	0.000281	0.00627	CbGeAlD
Sorafenib—RET—renal system—muscle cancer	0.000281	0.00627	CbGeAlD
Sorafenib—BRAF—bone marrow—muscle cancer	0.000279	0.00623	CbGeAlD
Sorafenib—KDR—embryo—muscle cancer	0.000276	0.00617	CbGeAlD
Sorafenib—EPHX2—tendon—muscle cancer	0.000276	0.00615	CbGeAlD
Sorafenib—ZAK—testis—muscle cancer	0.000272	0.00607	CbGeAlD
Sorafenib—RALBP1—smooth muscle tissue—muscle cancer	0.00027	0.00603	CbGeAlD
Sorafenib—MAP3K19—head—muscle cancer	0.00027	0.00603	CbGeAlD
Sorafenib—CSF1R—embryo—muscle cancer	0.00027	0.00602	CbGeAlD
Sorafenib—BRAF—vagina—muscle cancer	0.000268	0.00597	CbGeAlD
Sorafenib—HIPK3—testis—muscle cancer	0.000266	0.00594	CbGeAlD
Sorafenib—MAP3K7—cardiac atrium—muscle cancer	0.000266	0.00594	CbGeAlD
Sorafenib—FLT3—bone marrow—muscle cancer	0.000265	0.00591	CbGeAlD
Sorafenib—MAP3K19—testis—muscle cancer	0.000261	0.00582	CbGeAlD
Sorafenib—RALBP1—renal system—muscle cancer	0.00026	0.0058	CbGeAlD
Sorafenib—MKNK2—cardiac atrium—muscle cancer	0.000258	0.00576	CbGeAlD
Sorafenib—TIE1—head—muscle cancer	0.000258	0.00575	CbGeAlD
Sorafenib—FLT1—smooth muscle tissue—muscle cancer	0.000257	0.00574	CbGeAlD
Sorafenib—EPHX2—vagina—muscle cancer	0.000256	0.0057	CbGeAlD
Sorafenib—RAF1—smooth muscle tissue—muscle cancer	0.000256	0.0057	CbGeAlD
Sorafenib—MKNK1—cardiac atrium—muscle cancer	0.000255	0.00568	CbGeAlD
Sorafenib—TIE1—testis—muscle cancer	0.000249	0.00555	CbGeAlD
Sorafenib—FLT1—renal system—muscle cancer	0.000248	0.00552	CbGeAlD
Sorafenib—RAF1—renal system—muscle cancer	0.000246	0.00549	CbGeAlD
Sorafenib—FGFR1—tendon—muscle cancer	0.000245	0.00547	CbGeAlD
Sorafenib—KIT—embryo—muscle cancer	0.000245	0.00546	CbGeAlD
Sorafenib—PDGFRA—smooth muscle tissue—muscle cancer	0.000241	0.00537	CbGeAlD
Sorafenib—FLT4—bone marrow—muscle cancer	0.000241	0.00537	CbGeAlD
Sorafenib—PDGFRB—embryo—muscle cancer	0.000239	0.00534	CbGeAlD
Sorafenib—BRAF—testis—muscle cancer	0.000239	0.00533	CbGeAlD
Sorafenib—STK10—renal system—muscle cancer	0.000234	0.00523	CbGeAlD
Sorafenib—RALBP1—cardiac atrium—muscle cancer	0.000233	0.0052	CbGeAlD
Sorafenib—MAP3K7—tendon—muscle cancer	0.000232	0.00518	CbGeAlD
Sorafenib—PDGFRA—renal system—muscle cancer	0.000232	0.00517	CbGeAlD
Sorafenib—EPHX2—testis—muscle cancer	0.000228	0.00509	CbGeAlD
Sorafenib—FGFR1—vagina—muscle cancer	0.000227	0.00507	CbGeAlD
Sorafenib—FLT3—testis—muscle cancer	0.000227	0.00505	CbGeAlD
Sorafenib—MKNK2—tendon—muscle cancer	0.000225	0.00502	CbGeAlD
Sorafenib—MAP3K7—bone marrow—muscle cancer	0.000225	0.00501	CbGeAlD
Sorafenib—FLT1—cardiac atrium—muscle cancer	0.000222	0.00494	CbGeAlD
Sorafenib—UGT1A1—renal system—muscle cancer	0.000221	0.00494	CbGeAlD
Sorafenib—RAF1—cardiac atrium—muscle cancer	0.00022	0.00492	CbGeAlD
Sorafenib—RET—tendon—muscle cancer	0.000219	0.00489	CbGeAlD
Sorafenib—EPHB6—cardiac atrium—muscle cancer	0.000219	0.00489	CbGeAlD
Sorafenib—MKNK2—bone marrow—muscle cancer	0.000218	0.00486	CbGeAlD
Sorafenib—KDR—smooth muscle tissue—muscle cancer	0.000217	0.00485	CbGeAlD
Sorafenib—MAP3K7—vagina—muscle cancer	0.000215	0.0048	CbGeAlD
Sorafenib—MKNK1—bone marrow—muscle cancer	0.000215	0.0048	CbGeAlD
Sorafenib—FLT4—head—muscle cancer	0.000213	0.00475	CbGeAlD
Sorafenib—CSF1R—smooth muscle tissue—muscle cancer	0.000212	0.00473	CbGeAlD
Sorafenib—KDR—renal system—muscle cancer	0.000209	0.00467	CbGeAlD
Sorafenib—MKNK2—vagina—muscle cancer	0.000209	0.00466	CbGeAlD
Sorafenib—MKNK1—vagina—muscle cancer	0.000206	0.0046	CbGeAlD
Sorafenib—FLT4—testis—muscle cancer	0.000206	0.00459	CbGeAlD
Sorafenib—RALBP1—tendon—muscle cancer	0.000203	0.00453	CbGeAlD
Sorafenib—FGFR1—testis—muscle cancer	0.000203	0.00453	CbGeAlD
Sorafenib—RALBP1—bone marrow—muscle cancer	0.000197	0.00439	CbGeAlD
Sorafenib—FLT1—tendon—muscle cancer	0.000193	0.00431	CbGeAlD
Sorafenib—MKNK2—head—muscle cancer	0.000193	0.0043	CbGeAlD
Sorafenib—KIT—smooth muscle tissue—muscle cancer	0.000193	0.0043	CbGeAlD
Sorafenib—MAP3K7—testis—muscle cancer	0.000192	0.00429	CbGeAlD
Sorafenib—RAF1—tendon—muscle cancer	0.000192	0.00428	CbGeAlD
Sorafenib—EPHB6—tendon—muscle cancer	0.000191	0.00426	CbGeAlD
Sorafenib—MKNK1—head—muscle cancer	0.00019	0.00425	CbGeAlD
Sorafenib—RALBP1—vagina—muscle cancer	0.000188	0.0042	CbGeAlD
Sorafenib—PDGFRB—smooth muscle tissue—muscle cancer	0.000188	0.0042	CbGeAlD
Sorafenib—RET—head—muscle cancer	0.000188	0.00419	CbGeAlD
Sorafenib—KDR—cardiac atrium—muscle cancer	0.000187	0.00418	CbGeAlD
Sorafenib—MAP2K5—cardiac atrium—muscle cancer	0.000187	0.00418	CbGeAlD
Sorafenib—MKNK2—testis—muscle cancer	0.000186	0.00415	CbGeAlD
Sorafenib—RAF1—bone marrow—muscle cancer	0.000186	0.00415	CbGeAlD
Sorafenib—KIT—renal system—muscle cancer	0.000185	0.00414	CbGeAlD
Sorafenib—MKNK1—testis—muscle cancer	0.000184	0.0041	CbGeAlD
Sorafenib—STK10—tendon—muscle cancer	0.000183	0.00408	CbGeAlD
Sorafenib—CSF1R—cardiac atrium—muscle cancer	0.000183	0.00408	CbGeAlD
Sorafenib—RET—testis—muscle cancer	0.000182	0.00405	CbGeAlD
Sorafenib—PDGFRB—renal system—muscle cancer	0.000181	0.00404	CbGeAlD
Sorafenib—PDGFRA—tendon—muscle cancer	0.000181	0.00404	CbGeAlD
Sorafenib—FLT1—vagina—muscle cancer	0.000179	0.004	CbGeAlD
Sorafenib—RAF1—vagina—muscle cancer	0.000178	0.00398	CbGeAlD
Sorafenib—EPHB6—vagina—muscle cancer	0.000177	0.00395	CbGeAlD
Sorafenib—STK10—bone marrow—muscle cancer	0.000177	0.00395	CbGeAlD
Sorafenib—RALBP1—head—muscle cancer	0.000174	0.00388	CbGeAlD
Sorafenib—STK10—vagina—muscle cancer	0.00017	0.00379	CbGeAlD
Sorafenib—RALBP1—testis—muscle cancer	0.000168	0.00375	CbGeAlD
Sorafenib—PDGFRA—vagina—muscle cancer	0.000168	0.00375	CbGeAlD
Sorafenib—FLT1—head—muscle cancer	0.000166	0.00369	CbGeAlD
Sorafenib—RAF1—head—muscle cancer	0.000165	0.00367	CbGeAlD
Sorafenib—EPHB6—head—muscle cancer	0.000164	0.00365	CbGeAlD
Sorafenib—KDR—tendon—muscle cancer	0.000163	0.00364	CbGeAlD
Sorafenib—MAP2K5—tendon—muscle cancer	0.000163	0.00364	CbGeAlD
Sorafenib—PDGFRB—cardiac atrium—muscle cancer	0.000162	0.00362	CbGeAlD
Sorafenib—FLT1—testis—muscle cancer	0.00016	0.00357	CbGeAlD
Sorafenib—CSF1R—tendon—muscle cancer	0.000159	0.00356	CbGeAlD
Sorafenib—RAF1—testis—muscle cancer	0.000159	0.00355	CbGeAlD
Sorafenib—KDR—bone marrow—muscle cancer	0.000158	0.00353	CbGeAlD
Sorafenib—EPHB6—testis—muscle cancer	0.000158	0.00353	CbGeAlD
Sorafenib—STK10—head—muscle cancer	0.000157	0.0035	CbGeAlD
Sorafenib—PDGFRA—head—muscle cancer	0.000155	0.00346	CbGeAlD
Sorafenib—CSF1R—bone marrow—muscle cancer	0.000154	0.00344	CbGeAlD
Sorafenib—MAP2K5—vagina—muscle cancer	0.000152	0.00338	CbGeAlD
Sorafenib—KDR—vagina—muscle cancer	0.000152	0.00338	CbGeAlD
Sorafenib—STK10—testis—muscle cancer	0.000151	0.00338	CbGeAlD
Sorafenib—PDGFRA—testis—muscle cancer	0.00015	0.00334	CbGeAlD
Sorafenib—HTR2B—smooth muscle tissue—muscle cancer	0.000149	0.00332	CbGeAlD
Sorafenib—CSF1R—vagina—muscle cancer	0.000148	0.0033	CbGeAlD
Sorafenib—ABCC4—renal system—muscle cancer	0.000144	0.00322	CbGeAlD
Sorafenib—PDGFRB—tendon—muscle cancer	0.000141	0.00315	CbGeAlD
Sorafenib—KIT—bone marrow—muscle cancer	0.00014	0.00313	CbGeAlD
Sorafenib—MAP2K5—head—muscle cancer	0.00014	0.00312	CbGeAlD
Sorafenib—KDR—head—muscle cancer	0.00014	0.00312	CbGeAlD
Sorafenib—ABCC2—renal system—muscle cancer	0.00014	0.00311	CbGeAlD
Sorafenib—PDGFRB—bone marrow—muscle cancer	0.000137	0.00305	CbGeAlD
Sorafenib—CSF1R—head—muscle cancer	0.000137	0.00305	CbGeAlD
Sorafenib—MAP2K5—testis—muscle cancer	0.000135	0.00302	CbGeAlD
Sorafenib—KDR—testis—muscle cancer	0.000135	0.00302	CbGeAlD
Sorafenib—KIT—vagina—muscle cancer	0.000134	0.003	CbGeAlD
Sorafenib—CSF1R—testis—muscle cancer	0.000132	0.00294	CbGeAlD
Sorafenib—PDGFRB—vagina—muscle cancer	0.000131	0.00293	CbGeAlD
Sorafenib—KIT—head—muscle cancer	0.000124	0.00277	CbGeAlD
Sorafenib—PDGFRB—head—muscle cancer	0.000121	0.0027	CbGeAlD
Sorafenib—KIT—testis—muscle cancer	0.00012	0.00267	CbGeAlD
Sorafenib—PDGFRB—testis—muscle cancer	0.000117	0.00261	CbGeAlD
Sorafenib—ABCC4—tendon—muscle cancer	0.000113	0.00251	CbGeAlD
Sorafenib—HTR2B—tendon—muscle cancer	0.000112	0.0025	CbGeAlD
Sorafenib—Hepatobiliary disease—Etoposide—muscle cancer	0.000112	0.00253	CcSEcCtD
Sorafenib—ABCC4—bone marrow—muscle cancer	0.000109	0.00243	CbGeAlD
Sorafenib—ABCC2—tendon—muscle cancer	0.000109	0.00243	CbGeAlD
Sorafenib—Myalgia—Dactinomycin—muscle cancer	0.000109	0.00246	CcSEcCtD
Sorafenib—Influenza like illness—Doxorubicin—muscle cancer	0.000106	0.00241	CcSEcCtD
Sorafenib—Anaemia—Vincristine—muscle cancer	0.000105	0.00239	CcSEcCtD
Sorafenib—Urinary tract disorder—Etoposide—muscle cancer	0.000105	0.00237	CcSEcCtD
Sorafenib—CYP2C8—renal system—muscle cancer	0.000105	0.00234	CbGeAlD
Sorafenib—Skin exfoliation—Doxorubicin—muscle cancer	0.000105	0.00237	CcSEcCtD
Sorafenib—Urethral disorder—Etoposide—muscle cancer	0.000104	0.00235	CcSEcCtD
Sorafenib—HTR2B—vagina—muscle cancer	0.000104	0.00232	CbGeAlD
Sorafenib—Infection—Dactinomycin—muscle cancer	0.000103	0.00234	CcSEcCtD
Sorafenib—Neuropathy—Doxorubicin—muscle cancer	0.000103	0.00233	CcSEcCtD
Sorafenib—Hepatic failure—Methotrexate—muscle cancer	0.000102	0.00231	CcSEcCtD
Sorafenib—HTR2C—head—muscle cancer	0.000102	0.00228	CbGeAlD
Sorafenib—Leukopenia—Vincristine—muscle cancer	0.000102	0.00231	CcSEcCtD
Sorafenib—Thrombocytopenia—Dactinomycin—muscle cancer	0.000102	0.00231	CcSEcCtD
Sorafenib—Erythema multiforme—Etoposide—muscle cancer	0.0001	0.00227	CcSEcCtD
Sorafenib—Renal failure acute—Methotrexate—muscle cancer	9.95e-05	0.00225	CcSEcCtD
Sorafenib—Anorexia—Dactinomycin—muscle cancer	9.93e-05	0.00225	CcSEcCtD
Sorafenib—Mouth ulceration—Doxorubicin—muscle cancer	9.91e-05	0.00224	CcSEcCtD
Sorafenib—Neoplasm—Doxorubicin—muscle cancer	9.91e-05	0.00224	CcSEcCtD
Sorafenib—Flushing—Etoposide—muscle cancer	9.85e-05	0.00223	CcSEcCtD
Sorafenib—Cardiac disorder—Etoposide—muscle cancer	9.85e-05	0.00223	CcSEcCtD
Sorafenib—Hypertension—Vincristine—muscle cancer	9.84e-05	0.00223	CcSEcCtD
Sorafenib—CYP1A2—renal system—muscle cancer	9.8e-05	0.00219	CbGeAlD
Sorafenib—Dermatitis exfoliative—Methotrexate—muscle cancer	9.74e-05	0.0022	CcSEcCtD
Sorafenib—Myalgia—Vincristine—muscle cancer	9.71e-05	0.0022	CcSEcCtD
Sorafenib—ABCC4—head—muscle cancer	9.65e-05	0.00215	CbGeAlD
Sorafenib—Angiopathy—Etoposide—muscle cancer	9.63e-05	0.00218	CcSEcCtD
Sorafenib—HTR2B—head—muscle cancer	9.6e-05	0.00214	CbGeAlD
Sorafenib—Immune system disorder—Etoposide—muscle cancer	9.58e-05	0.00217	CcSEcCtD
Sorafenib—Mediastinal disorder—Etoposide—muscle cancer	9.56e-05	0.00216	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Dactinomycin—muscle cancer	9.49e-05	0.00215	CcSEcCtD
Sorafenib—CYP3A5—renal system—muscle cancer	9.45e-05	0.00211	CbGeAlD
Sorafenib—CYP2B6—renal system—muscle cancer	9.39e-05	0.00209	CbGeAlD
Sorafenib—Alopecia—Etoposide—muscle cancer	9.38e-05	0.00212	CcSEcCtD
Sorafenib—ABCC4—testis—muscle cancer	9.32e-05	0.00208	CbGeAlD
Sorafenib—Anaphylactic shock—Vincristine—muscle cancer	9.31e-05	0.00211	CcSEcCtD
Sorafenib—Infection—Vincristine—muscle cancer	9.25e-05	0.00209	CcSEcCtD
Sorafenib—Nervous system disorder—Vincristine—muscle cancer	9.13e-05	0.00207	CcSEcCtD
Sorafenib—Thrombocytopenia—Vincristine—muscle cancer	9.11e-05	0.00206	CcSEcCtD
Sorafenib—Hepatic function abnormal—Doxorubicin—muscle cancer	9.1e-05	0.00206	CcSEcCtD
Sorafenib—Decreased appetite—Dactinomycin—muscle cancer	9.05e-05	0.00205	CcSEcCtD
Sorafenib—Dysgeusia—Etoposide—muscle cancer	9.05e-05	0.00205	CcSEcCtD
Sorafenib—ABCC2—testis—muscle cancer	9.02e-05	0.00201	CbGeAlD
Sorafenib—Fatigue—Dactinomycin—muscle cancer	8.98e-05	0.00203	CcSEcCtD
Sorafenib—Pain—Dactinomycin—muscle cancer	8.91e-05	0.00202	CcSEcCtD
Sorafenib—Muscle spasms—Etoposide—muscle cancer	8.88e-05	0.00201	CcSEcCtD
Sorafenib—Anorexia—Vincristine—muscle cancer	8.87e-05	0.00201	CcSEcCtD
Sorafenib—Hepatic failure—Doxorubicin—muscle cancer	8.85e-05	0.002	CcSEcCtD
Sorafenib—Eczema—Doxorubicin—muscle cancer	8.85e-05	0.002	CcSEcCtD
Sorafenib—Cardiac failure congestive—Doxorubicin—muscle cancer	8.77e-05	0.00199	CcSEcCtD
Sorafenib—Mood swings—Methotrexate—muscle cancer	8.7e-05	0.00197	CcSEcCtD
Sorafenib—CYP2C19—vagina—muscle cancer	8.69e-05	0.00194	CbGeAlD
Sorafenib—Renal failure acute—Doxorubicin—muscle cancer	8.62e-05	0.00195	CcSEcCtD
Sorafenib—Anaemia—Etoposide—muscle cancer	8.54e-05	0.00193	CcSEcCtD
Sorafenib—Gastrointestinal pain—Dactinomycin—muscle cancer	8.52e-05	0.00193	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Vincristine—muscle cancer	8.48e-05	0.00192	CcSEcCtD
Sorafenib—Dermatitis exfoliative—Doxorubicin—muscle cancer	8.43e-05	0.00191	CcSEcCtD
Sorafenib—Breast disorder—Methotrexate—muscle cancer	8.3e-05	0.00188	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Methotrexate—muscle cancer	8.27e-05	0.00187	CcSEcCtD
Sorafenib—Leukopenia—Etoposide—muscle cancer	8.27e-05	0.00187	CcSEcCtD
Sorafenib—Abdominal pain—Dactinomycin—muscle cancer	8.23e-05	0.00186	CcSEcCtD
Sorafenib—Body temperature increased—Dactinomycin—muscle cancer	8.23e-05	0.00186	CcSEcCtD
Sorafenib—Cardiac failure—Doxorubicin—muscle cancer	8.15e-05	0.00184	CcSEcCtD
Sorafenib—Loss of consciousness—Etoposide—muscle cancer	8.12e-05	0.00184	CcSEcCtD
Sorafenib—Decreased appetite—Vincristine—muscle cancer	8.09e-05	0.00183	CcSEcCtD
Sorafenib—Cough—Etoposide—muscle cancer	8.06e-05	0.00182	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Vincristine—muscle cancer	8.03e-05	0.00182	CcSEcCtD
Sorafenib—Fatigue—Vincristine—muscle cancer	8.02e-05	0.00182	CcSEcCtD
Sorafenib—Hyponatraemia—Doxorubicin—muscle cancer	7.99e-05	0.00181	CcSEcCtD
Sorafenib—Hypertension—Etoposide—muscle cancer	7.97e-05	0.0018	CcSEcCtD
Sorafenib—Pain—Vincristine—muscle cancer	7.96e-05	0.0018	CcSEcCtD
Sorafenib—Constipation—Vincristine—muscle cancer	7.96e-05	0.0018	CcSEcCtD
Sorafenib—Pain in extremity—Doxorubicin—muscle cancer	7.96e-05	0.0018	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	7.81e-05	0.00177	CcSEcCtD
Sorafenib—Pancreatitis—Methotrexate—muscle cancer	7.79e-05	0.00176	CcSEcCtD
Sorafenib—ABCG2—bone marrow—muscle cancer	7.7e-05	0.00172	CbGeAlD
Sorafenib—Hypersensitivity—Dactinomycin—muscle cancer	7.67e-05	0.00174	CcSEcCtD
Sorafenib—Abdominal discomfort—Methotrexate—muscle cancer	7.61e-05	0.00172	CcSEcCtD
Sorafenib—Gastrointestinal pain—Vincristine—muscle cancer	7.61e-05	0.00172	CcSEcCtD
Sorafenib—CYP2C8—vagina—muscle cancer	7.58e-05	0.00169	CbGeAlD
Sorafenib—Anaphylactic shock—Etoposide—muscle cancer	7.54e-05	0.00171	CcSEcCtD
Sorafenib—Mood swings—Doxorubicin—muscle cancer	7.54e-05	0.00171	CcSEcCtD
Sorafenib—Infection—Etoposide—muscle cancer	7.49e-05	0.0017	CcSEcCtD
Sorafenib—Asthenia—Dactinomycin—muscle cancer	7.47e-05	0.00169	CcSEcCtD
Sorafenib—Neutropenia—Methotrexate—muscle cancer	7.43e-05	0.00168	CcSEcCtD
Sorafenib—Dehydration—Doxorubicin—muscle cancer	7.4e-05	0.00167	CcSEcCtD
Sorafenib—Thrombocytopenia—Etoposide—muscle cancer	7.38e-05	0.00167	CcSEcCtD
Sorafenib—ABCG2—vagina—muscle cancer	7.37e-05	0.00164	CbGeAlD
Sorafenib—Abdominal pain—Vincristine—muscle cancer	7.36e-05	0.00167	CcSEcCtD
Sorafenib—Body temperature increased—Vincristine—muscle cancer	7.36e-05	0.00167	CcSEcCtD
Sorafenib—Skin disorder—Etoposide—muscle cancer	7.32e-05	0.00166	CcSEcCtD
Sorafenib—Erectile dysfunction—Methotrexate—muscle cancer	7.31e-05	0.00166	CcSEcCtD
Sorafenib—Dry skin—Doxorubicin—muscle cancer	7.29e-05	0.00165	CcSEcCtD
Sorafenib—Abdominal pain upper—Doxorubicin—muscle cancer	7.27e-05	0.00164	CcSEcCtD
Sorafenib—Hypokalaemia—Doxorubicin—muscle cancer	7.24e-05	0.00164	CcSEcCtD
Sorafenib—Breast disorder—Doxorubicin—muscle cancer	7.19e-05	0.00163	CcSEcCtD
Sorafenib—Anorexia—Etoposide—muscle cancer	7.19e-05	0.00163	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	7.16e-05	0.00162	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	7.16e-05	0.00162	CcSEcCtD
Sorafenib—Diarrhoea—Dactinomycin—muscle cancer	7.13e-05	0.00161	CcSEcCtD
Sorafenib—Pneumonia—Methotrexate—muscle cancer	7.12e-05	0.00161	CcSEcCtD
Sorafenib—Nasopharyngitis—Doxorubicin—muscle cancer	7.11e-05	0.00161	CcSEcCtD
Sorafenib—CYP3A4—renal system—muscle cancer	7.09e-05	0.00158	CbGeAlD
Sorafenib—Infestation NOS—Methotrexate—muscle cancer	7.08e-05	0.0016	CcSEcCtD
Sorafenib—Infestation—Methotrexate—muscle cancer	7.08e-05	0.0016	CcSEcCtD
Sorafenib—Gastritis—Doxorubicin—muscle cancer	7.04e-05	0.00159	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—muscle cancer	7.02e-05	0.00159	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	7.02e-05	0.00159	CcSEcCtD
Sorafenib—CYP2D6—renal system—muscle cancer	6.98e-05	0.00156	CbGeAlD
Sorafenib—Renal failure—Methotrexate—muscle cancer	6.96e-05	0.00158	CcSEcCtD
Sorafenib—Stomatitis—Methotrexate—muscle cancer	6.9e-05	0.00156	CcSEcCtD
Sorafenib—Dysphagia—Doxorubicin—muscle cancer	6.88e-05	0.00156	CcSEcCtD
Sorafenib—Hypersensitivity—Vincristine—muscle cancer	6.86e-05	0.00155	CcSEcCtD
Sorafenib—CYP3A5—vagina—muscle cancer	6.84e-05	0.00153	CbGeAlD
Sorafenib—CYP2B6—vagina—muscle cancer	6.8e-05	0.00152	CbGeAlD
Sorafenib—CYP2C8—testis—muscle cancer	6.77e-05	0.00151	CbGeAlD
Sorafenib—Pancreatitis—Doxorubicin—muscle cancer	6.74e-05	0.00153	CcSEcCtD
Sorafenib—Dyspnoea—Etoposide—muscle cancer	6.72e-05	0.00152	CcSEcCtD
Sorafenib—Hepatobiliary disease—Methotrexate—muscle cancer	6.7e-05	0.00152	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—muscle cancer	6.68e-05	0.00151	CcSEcCtD
Sorafenib—Asthenia—Vincristine—muscle cancer	6.68e-05	0.00151	CcSEcCtD
Sorafenib—ABCB1—embryo—muscle cancer	6.63e-05	0.00148	CbGeAlD
Sorafenib—Vomiting—Dactinomycin—muscle cancer	6.62e-05	0.0015	CcSEcCtD
Sorafenib—ABCG2—testis—muscle cancer	6.58e-05	0.00147	CbGeAlD
Sorafenib—Rash—Dactinomycin—muscle cancer	6.57e-05	0.00149	CcSEcCtD
Sorafenib—Decreased appetite—Etoposide—muscle cancer	6.55e-05	0.00148	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Etoposide—muscle cancer	6.51e-05	0.00147	CcSEcCtD
Sorafenib—Fatigue—Etoposide—muscle cancer	6.5e-05	0.00147	CcSEcCtD
Sorafenib—Pain—Etoposide—muscle cancer	6.45e-05	0.00146	CcSEcCtD
Sorafenib—Constipation—Etoposide—muscle cancer	6.45e-05	0.00146	CcSEcCtD
Sorafenib—Neutropenia—Doxorubicin—muscle cancer	6.43e-05	0.00146	CcSEcCtD
Sorafenib—Haemoglobin—Methotrexate—muscle cancer	6.39e-05	0.00145	CcSEcCtD
Sorafenib—Diarrhoea—Vincristine—muscle cancer	6.37e-05	0.00144	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—muscle cancer	6.36e-05	0.00144	CcSEcCtD
Sorafenib—CYP2B6—head—muscle cancer	6.28e-05	0.0014	CbGeAlD
Sorafenib—Urinary tract disorder—Methotrexate—muscle cancer	6.28e-05	0.00142	CcSEcCtD
Sorafenib—Urethral disorder—Methotrexate—muscle cancer	6.23e-05	0.00141	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—muscle cancer	6.22e-05	0.00141	CcSEcCtD
Sorafenib—Nausea—Dactinomycin—muscle cancer	6.19e-05	0.0014	CcSEcCtD
Sorafenib—Pneumonia—Doxorubicin—muscle cancer	6.17e-05	0.0014	CcSEcCtD
Sorafenib—Gastrointestinal pain—Etoposide—muscle cancer	6.16e-05	0.0014	CcSEcCtD
Sorafenib—Dizziness—Vincristine—muscle cancer	6.15e-05	0.00139	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—muscle cancer	6.13e-05	0.00139	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—muscle cancer	6.13e-05	0.00139	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	6.08e-05	0.00138	CcSEcCtD
Sorafenib—CYP2B6—testis—muscle cancer	6.07e-05	0.00135	CbGeAlD
Sorafenib—Renal failure—Doxorubicin—muscle cancer	6.03e-05	0.00136	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—muscle cancer	6.01e-05	0.00136	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—muscle cancer	6.01e-05	0.00136	CcSEcCtD
Sorafenib—Urticaria—Etoposide—muscle cancer	5.99e-05	0.00136	CcSEcCtD
Sorafenib—Stomatitis—Doxorubicin—muscle cancer	5.98e-05	0.00135	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—muscle cancer	5.98e-05	0.00135	CcSEcCtD
Sorafenib—Abdominal pain—Etoposide—muscle cancer	5.96e-05	0.00135	CcSEcCtD
Sorafenib—Body temperature increased—Etoposide—muscle cancer	5.96e-05	0.00135	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—muscle cancer	5.93e-05	0.00134	CcSEcCtD
Sorafenib—Vomiting—Vincristine—muscle cancer	5.92e-05	0.00134	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—muscle cancer	5.9e-05	0.00134	CcSEcCtD
Sorafenib—Rash—Vincristine—muscle cancer	5.87e-05	0.00133	CcSEcCtD
Sorafenib—Dermatitis—Vincristine—muscle cancer	5.86e-05	0.00133	CcSEcCtD
Sorafenib—Headache—Vincristine—muscle cancer	5.83e-05	0.00132	CcSEcCtD
Sorafenib—Hepatobiliary disease—Doxorubicin—muscle cancer	5.8e-05	0.00131	CcSEcCtD
Sorafenib—Epistaxis—Doxorubicin—muscle cancer	5.78e-05	0.00131	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—muscle cancer	5.77e-05	0.00131	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—muscle cancer	5.74e-05	0.0013	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—muscle cancer	5.73e-05	0.0013	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—muscle cancer	5.62e-05	0.00127	CcSEcCtD
Sorafenib—Mental disorder—Methotrexate—muscle cancer	5.57e-05	0.00126	CcSEcCtD
Sorafenib—Hypersensitivity—Etoposide—muscle cancer	5.55e-05	0.00126	CcSEcCtD
Sorafenib—Erythema—Methotrexate—muscle cancer	5.53e-05	0.00125	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—muscle cancer	5.53e-05	0.00125	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—muscle cancer	5.53e-05	0.00125	CcSEcCtD
Sorafenib—Nausea—Vincristine—muscle cancer	5.53e-05	0.00125	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—muscle cancer	5.5e-05	0.00125	CcSEcCtD
Sorafenib—Urinary tract disorder—Doxorubicin—muscle cancer	5.44e-05	0.00123	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—muscle cancer	5.42e-05	0.00123	CcSEcCtD
Sorafenib—Asthenia—Etoposide—muscle cancer	5.41e-05	0.00122	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—muscle cancer	5.41e-05	0.00122	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—muscle cancer	5.39e-05	0.00122	CcSEcCtD
Sorafenib—Pruritus—Etoposide—muscle cancer	5.33e-05	0.00121	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—muscle cancer	5.2e-05	0.00118	CcSEcCtD
Sorafenib—Diarrhoea—Etoposide—muscle cancer	5.16e-05	0.00117	CcSEcCtD
Sorafenib—Tinnitus—Doxorubicin—muscle cancer	5.13e-05	0.00116	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—muscle cancer	5.11e-05	0.00116	CcSEcCtD
Sorafenib—Flushing—Doxorubicin—muscle cancer	5.11e-05	0.00116	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—muscle cancer	5.11e-05	0.00116	CcSEcCtD
Sorafenib—ABCB1—renal system—muscle cancer	5.02e-05	0.00112	CbGeAlD
Sorafenib—Angiopathy—Doxorubicin—muscle cancer	4.99e-05	0.00113	CcSEcCtD
Sorafenib—Dizziness—Etoposide—muscle cancer	4.99e-05	0.00113	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—muscle cancer	4.97e-05	0.00113	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—muscle cancer	4.96e-05	0.00112	CcSEcCtD
Sorafenib—Leukopenia—Methotrexate—muscle cancer	4.95e-05	0.00112	CcSEcCtD
Sorafenib—Arrhythmia—Doxorubicin—muscle cancer	4.92e-05	0.00111	CcSEcCtD
Sorafenib—Alopecia—Doxorubicin—muscle cancer	4.86e-05	0.0011	CcSEcCtD
Sorafenib—Cough—Methotrexate—muscle cancer	4.83e-05	0.00109	CcSEcCtD
Sorafenib—Mental disorder—Doxorubicin—muscle cancer	4.82e-05	0.00109	CcSEcCtD
Sorafenib—Vomiting—Etoposide—muscle cancer	4.79e-05	0.00108	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—muscle cancer	4.79e-05	0.00108	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—muscle cancer	4.79e-05	0.00108	CcSEcCtD
Sorafenib—Rash—Etoposide—muscle cancer	4.75e-05	0.00108	CcSEcCtD
Sorafenib—Dermatitis—Etoposide—muscle cancer	4.75e-05	0.00107	CcSEcCtD
Sorafenib—Headache—Etoposide—muscle cancer	4.72e-05	0.00107	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—muscle cancer	4.71e-05	0.00107	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—muscle cancer	4.71e-05	0.00107	CcSEcCtD
Sorafenib—Dysgeusia—Doxorubicin—muscle cancer	4.69e-05	0.00106	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	4.68e-05	0.00106	CcSEcCtD
Sorafenib—CYP2D6—head—muscle cancer	4.67e-05	0.00104	CbGeAlD
Sorafenib—Muscle spasms—Doxorubicin—muscle cancer	4.61e-05	0.00104	CcSEcCtD
Sorafenib—Anaphylactic shock—Methotrexate—muscle cancer	4.52e-05	0.00102	CcSEcCtD
Sorafenib—CYP2D6—testis—muscle cancer	4.51e-05	0.00101	CbGeAlD
Sorafenib—Infection—Methotrexate—muscle cancer	4.49e-05	0.00102	CcSEcCtD
Sorafenib—Nausea—Etoposide—muscle cancer	4.48e-05	0.00101	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—muscle cancer	4.43e-05	0.001	CcSEcCtD
Sorafenib—Anaemia—Doxorubicin—muscle cancer	4.43e-05	0.001	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—muscle cancer	4.42e-05	0.001	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—muscle cancer	4.39e-05	0.000993	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—muscle cancer	4.3e-05	0.000974	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—muscle cancer	4.3e-05	0.000972	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—muscle cancer	4.29e-05	0.000971	CcSEcCtD
Sorafenib—Loss of consciousness—Doxorubicin—muscle cancer	4.21e-05	0.000953	CcSEcCtD
Sorafenib—Cough—Doxorubicin—muscle cancer	4.18e-05	0.000946	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—muscle cancer	4.14e-05	0.000936	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methotrexate—muscle cancer	4.11e-05	0.000931	CcSEcCtD
Sorafenib—Arthralgia—Doxorubicin—muscle cancer	4.08e-05	0.000923	CcSEcCtD
Sorafenib—Myalgia—Doxorubicin—muscle cancer	4.08e-05	0.000923	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	4.05e-05	0.000917	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—muscle cancer	4.03e-05	0.000911	CcSEcCtD
Sorafenib—Dry mouth—Doxorubicin—muscle cancer	3.99e-05	0.000903	CcSEcCtD
Sorafenib—Dyspepsia—Methotrexate—muscle cancer	3.97e-05	0.0009	CcSEcCtD
Sorafenib—Decreased appetite—Methotrexate—muscle cancer	3.93e-05	0.000888	CcSEcCtD
Sorafenib—Anaphylactic shock—Doxorubicin—muscle cancer	3.91e-05	0.000885	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—muscle cancer	3.9e-05	0.000882	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—muscle cancer	3.89e-05	0.000881	CcSEcCtD
Sorafenib—Infection—Doxorubicin—muscle cancer	3.88e-05	0.000879	CcSEcCtD
Sorafenib—Pain—Methotrexate—muscle cancer	3.86e-05	0.000874	CcSEcCtD
Sorafenib—Shock—Doxorubicin—muscle cancer	3.85e-05	0.000871	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—muscle cancer	3.83e-05	0.000868	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—muscle cancer	3.83e-05	0.000866	CcSEcCtD
Sorafenib—Skin disorder—Doxorubicin—muscle cancer	3.8e-05	0.00086	CcSEcCtD
Sorafenib—ABCB1—bone marrow—muscle cancer	3.8e-05	0.000847	CbGeAlD
Sorafenib—Anorexia—Doxorubicin—muscle cancer	3.73e-05	0.000844	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—muscle cancer	3.69e-05	0.000836	CcSEcCtD
Sorafenib—ABCB1—vagina—muscle cancer	3.64e-05	0.000811	CbGeAlD
Sorafenib—Urticaria—Methotrexate—muscle cancer	3.59e-05	0.000812	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—muscle cancer	3.57e-05	0.000808	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—muscle cancer	3.57e-05	0.000808	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	3.56e-05	0.000806	CcSEcCtD
Sorafenib—Dyspnoea—Doxorubicin—muscle cancer	3.49e-05	0.000789	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—muscle cancer	3.44e-05	0.000779	CcSEcCtD
Sorafenib—Decreased appetite—Doxorubicin—muscle cancer	3.4e-05	0.000769	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—muscle cancer	3.38e-05	0.000764	CcSEcCtD
Sorafenib—Fatigue—Doxorubicin—muscle cancer	3.37e-05	0.000763	CcSEcCtD
Sorafenib—ABCB1—head—muscle cancer	3.36e-05	0.000749	CbGeAlD
Sorafenib—Constipation—Doxorubicin—muscle cancer	3.34e-05	0.000757	CcSEcCtD
Sorafenib—Pain—Doxorubicin—muscle cancer	3.34e-05	0.000757	CcSEcCtD
Sorafenib—Hypersensitivity—Methotrexate—muscle cancer	3.33e-05	0.000753	CcSEcCtD
Sorafenib—ABCB1—testis—muscle cancer	3.24e-05	0.000724	CbGeAlD
Sorafenib—Asthenia—Methotrexate—muscle cancer	3.24e-05	0.000733	CcSEcCtD
Sorafenib—Gastrointestinal pain—Doxorubicin—muscle cancer	3.2e-05	0.000724	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—muscle cancer	3.19e-05	0.000723	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—muscle cancer	3.11e-05	0.000703	CcSEcCtD
Sorafenib—Abdominal pain—Doxorubicin—muscle cancer	3.09e-05	0.0007	CcSEcCtD
Sorafenib—Body temperature increased—Doxorubicin—muscle cancer	3.09e-05	0.0007	CcSEcCtD
Sorafenib—Diarrhoea—Methotrexate—muscle cancer	3.09e-05	0.000699	CcSEcCtD
Sorafenib—Dizziness—Methotrexate—muscle cancer	2.99e-05	0.000676	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—muscle cancer	2.88e-05	0.000652	CcSEcCtD
Sorafenib—Vomiting—Methotrexate—muscle cancer	2.87e-05	0.00065	CcSEcCtD
Sorafenib—Rash—Methotrexate—muscle cancer	2.85e-05	0.000644	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—muscle cancer	2.84e-05	0.000644	CcSEcCtD
Sorafenib—Headache—Methotrexate—muscle cancer	2.83e-05	0.00064	CcSEcCtD
Sorafenib—Asthenia—Doxorubicin—muscle cancer	2.81e-05	0.000635	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—muscle cancer	2.77e-05	0.000626	CcSEcCtD
Sorafenib—Nausea—Methotrexate—muscle cancer	2.68e-05	0.000607	CcSEcCtD
Sorafenib—Diarrhoea—Doxorubicin—muscle cancer	2.68e-05	0.000605	CcSEcCtD
Sorafenib—Dizziness—Doxorubicin—muscle cancer	2.59e-05	0.000585	CcSEcCtD
Sorafenib—Vomiting—Doxorubicin—muscle cancer	2.49e-05	0.000563	CcSEcCtD
Sorafenib—Rash—Doxorubicin—muscle cancer	2.47e-05	0.000558	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—muscle cancer	2.46e-05	0.000557	CcSEcCtD
Sorafenib—Headache—Doxorubicin—muscle cancer	2.45e-05	0.000554	CcSEcCtD
Sorafenib—Nausea—Doxorubicin—muscle cancer	2.32e-05	0.000526	CcSEcCtD
Sorafenib—PDGFRB—Innate Immune System—KIT—muscle cancer	8.91e-06	0.000163	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—FOXO1—muscle cancer	8.86e-06	0.000162	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CNR1—muscle cancer	8.85e-06	0.000162	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CNR1—muscle cancer	8.83e-06	0.000162	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—MED12—muscle cancer	8.79e-06	0.000161	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—MED12—muscle cancer	8.79e-06	0.000161	CbGpPWpGaD
Sorafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	8.69e-06	0.000159	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—KIT—muscle cancer	8.56e-06	0.000157	CbGpPWpGaD
Sorafenib—CDK7—Disease—KIT—muscle cancer	8.53e-06	0.000156	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—FOXO4—muscle cancer	8.52e-06	0.000156	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—KIT—muscle cancer	8.47e-06	0.000155	CbGpPWpGaD
Sorafenib—RAF1—Disease—HMGA1—muscle cancer	8.47e-06	0.000155	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	8.46e-06	0.000155	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CNR1—muscle cancer	8.4e-06	0.000154	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—MDM2—muscle cancer	8.23e-06	0.000151	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—MDM2—muscle cancer	8.23e-06	0.000151	CbGpPWpGaD
Sorafenib—RAF1—Immune System—FOXO4—muscle cancer	8.22e-06	0.00015	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—FH—muscle cancer	8.2e-06	0.00015	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—MDM2—muscle cancer	8.19e-06	0.00015	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PTCH1—muscle cancer	8.13e-06	0.000149	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PTCH1—muscle cancer	8.13e-06	0.000149	CbGpPWpGaD
Sorafenib—BRAF—Disease—FOXO1—muscle cancer	8.1e-06	0.000148	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—MDM2—muscle cancer	8.05e-06	0.000147	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ENO2—muscle cancer	8.02e-06	0.000147	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ENO2—muscle cancer	8.02e-06	0.000147	CbGpPWpGaD
Sorafenib—KIT—Immune System—FOXO1—muscle cancer	7.99e-06	0.000146	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—FOXO1—muscle cancer	7.99e-06	0.000146	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—KIT—muscle cancer	7.95e-06	0.000145	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—MDM2—muscle cancer	7.91e-06	0.000145	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—MDM2—muscle cancer	7.91e-06	0.000145	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—VEGFA—muscle cancer	7.85e-06	0.000144	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—MDM2—muscle cancer	7.81e-06	0.000143	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—MDM2—muscle cancer	7.79e-06	0.000142	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FOXO4—muscle cancer	7.76e-06	0.000142	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PTCH1—muscle cancer	7.72e-06	0.000141	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PTCH1—muscle cancer	7.7e-06	0.000141	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FOXO4—muscle cancer	7.68e-06	0.00014	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—KIT—muscle cancer	7.63e-06	0.000139	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—KIT—muscle cancer	7.63e-06	0.000139	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CNR1—muscle cancer	7.63e-06	0.000139	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CNR1—muscle cancer	7.61e-06	0.000139	CbGpPWpGaD
Sorafenib—RAF1—Disease—FOXO4—muscle cancer	7.59e-06	0.000139	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—FOXO1—muscle cancer	7.58e-06	0.000139	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—FOXO1—muscle cancer	7.56e-06	0.000138	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CNR1—muscle cancer	7.54e-06	0.000138	CbGpPWpGaD
Sorafenib—RAF1—Axon guidance—VEGFA—muscle cancer	7.54e-06	0.000138	CbGpPWpGaD
Sorafenib—CDK7—Cell Cycle—TP53—muscle cancer	7.51e-06	0.000137	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—MDM2—muscle cancer	7.5e-06	0.000137	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—MDM2—muscle cancer	7.48e-06	0.000137	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—MED12—muscle cancer	7.46e-06	0.000136	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IGF2—muscle cancer	7.43e-06	0.000136	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—MED12—muscle cancer	7.4e-06	0.000135	CbGpPWpGaD
Sorafenib—KIT—Disease—FOXO1—muscle cancer	7.38e-06	0.000135	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—FH—muscle cancer	7.32e-06	0.000134	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IGF2—muscle cancer	7.24e-06	0.000132	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	7.23e-06	0.000132	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	7.15e-06	0.000131	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—FH—muscle cancer	7.14e-06	0.000131	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—MDM2—muscle cancer	7.02e-06	0.000128	CbGpPWpGaD
Sorafenib—FGFR1—Disease—FOXO1—muscle cancer	7e-06	0.000128	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FOXO4—muscle cancer	6.99e-06	0.000128	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FOXO4—muscle cancer	6.99e-06	0.000128	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—FOXO1—muscle cancer	6.98e-06	0.000128	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PTCH1—muscle cancer	6.94e-06	0.000127	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	6.89e-06	0.000126	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CNR1—muscle cancer	6.87e-06	0.000126	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CNR1—muscle cancer	6.87e-06	0.000126	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—FOXO1—muscle cancer	6.84e-06	0.000125	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—FOXO1—muscle cancer	6.81e-06	0.000125	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ENO2—muscle cancer	6.8e-06	0.000124	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—KIT—muscle cancer	6.75e-06	0.000123	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ENO2—muscle cancer	6.74e-06	0.000123	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—MDM2—muscle cancer	6.74e-06	0.000123	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—FH—muscle cancer	6.73e-06	0.000123	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—VEGFA—muscle cancer	6.72e-06	0.000123	CbGpPWpGaD
Sorafenib—CDK7—Disease—MDM2—muscle cancer	6.71e-06	0.000123	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—MDM2—muscle cancer	6.67e-06	0.000122	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—FH—muscle cancer	6.67e-06	0.000122	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—FOXO1—muscle cancer	6.66e-06	0.000122	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FOXO4—muscle cancer	6.64e-06	0.000121	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FOXO4—muscle cancer	6.62e-06	0.000121	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTCH1—muscle cancer	6.62e-06	0.000121	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CNR1—muscle cancer	6.52e-06	0.000119	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CNR1—muscle cancer	6.5e-06	0.000119	CbGpPWpGaD
Sorafenib—CDK7—Disease—PTGS2—muscle cancer	6.47e-06	0.000118	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—FOXO1—muscle cancer	6.29e-06	0.000115	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—VEGFA—muscle cancer	6.28e-06	0.000115	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.27e-06	0.000115	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—MDM2—muscle cancer	6.26e-06	0.000114	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IGF2—muscle cancer	6.23e-06	0.000114	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—VEGFA—muscle cancer	6.22e-06	0.000114	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTCH1—muscle cancer	6.18e-06	0.000113	CbGpPWpGaD
Sorafenib—BRAF—Disease—KIT—muscle cancer	6.18e-06	0.000113	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IGF2—muscle cancer	6.17e-06	0.000113	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—VEGFA—muscle cancer	6.12e-06	0.000112	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—KIT—muscle cancer	6.09e-06	0.000111	CbGpPWpGaD
Sorafenib—RAF1—Immune System—FOXO1—muscle cancer	6.07e-06	0.000111	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—MDM2—muscle cancer	6.01e-06	0.00011	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—MDM2—muscle cancer	6.01e-06	0.00011	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FOXO4—muscle cancer	5.97e-06	0.000109	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CNR1—muscle cancer	5.86e-06	0.000107	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—KIT—muscle cancer	5.78e-06	0.000106	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—KIT—muscle cancer	5.76e-06	0.000105	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FOXO1—muscle cancer	5.73e-06	0.000105	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—FH—muscle cancer	5.7e-06	0.000104	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FOXO4—muscle cancer	5.69e-06	0.000104	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FOXO1—muscle cancer	5.68e-06	0.000104	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IGF2—muscle cancer	5.61e-06	0.000103	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IGF2—muscle cancer	5.61e-06	0.000103	CbGpPWpGaD
Sorafenib—RAF1—Disease—FOXO1—muscle cancer	5.61e-06	0.000103	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CNR1—muscle cancer	5.58e-06	0.000102	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MED12—muscle cancer	5.47e-06	0.0001	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	5.43e-06	9.92e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—VEGFA—muscle cancer	5.38e-06	9.84e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MED12—muscle cancer	5.35e-06	9.78e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTCH1—muscle cancer	5.34e-06	9.76e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—KIT—muscle cancer	5.33e-06	9.75e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IGF2—muscle cancer	5.33e-06	9.74e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—KIT—muscle cancer	5.32e-06	9.73e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—MDM2—muscle cancer	5.32e-06	9.72e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FOXO4—muscle cancer	5.32e-06	9.72e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IGF2—muscle cancer	5.31e-06	9.71e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—VEGFA—muscle cancer	5.28e-06	9.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CNR1—muscle cancer	5.22e-06	9.54e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—KIT—muscle cancer	5.21e-06	9.52e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KIT—muscle cancer	5.19e-06	9.49e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FOXO1—muscle cancer	5.17e-06	9.44e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FOXO1—muscle cancer	5.17e-06	9.44e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KIT—muscle cancer	5.08e-06	9.28e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—VEGFA—muscle cancer	5.07e-06	9.27e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ENO2—muscle cancer	4.99e-06	9.12e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FOXO1—muscle cancer	4.9e-06	8.96e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FOXO1—muscle cancer	4.89e-06	8.94e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ENO2—muscle cancer	4.87e-06	8.91e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—MDM2—muscle cancer	4.86e-06	8.89e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—MDM2—muscle cancer	4.79e-06	8.77e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—MDM2—muscle cancer	4.79e-06	8.77e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KIT—muscle cancer	4.79e-06	8.76e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IGF2—muscle cancer	4.79e-06	8.75e-05	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—TP53—muscle cancer	4.74e-06	8.67e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—TP53—muscle cancer	4.7e-06	8.59e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—PTGS2—muscle cancer	4.69e-06	8.57e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MED12—muscle cancer	4.63e-06	8.47e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KIT—muscle cancer	4.63e-06	8.46e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—TP53—muscle cancer	4.62e-06	8.45e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FOXO4—muscle cancer	4.59e-06	8.39e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IGF2—muscle cancer	4.57e-06	8.35e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—VEGFA—muscle cancer	4.56e-06	8.34e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—MDM2—muscle cancer	4.55e-06	8.32e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—MDM2—muscle cancer	4.54e-06	8.3e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CNR1—muscle cancer	4.5e-06	8.24e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—MDM2—muscle cancer	4.43e-06	8.09e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FOXO1—muscle cancer	4.41e-06	8.05e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—FH—muscle cancer	4.4e-06	8.04e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KIT—muscle cancer	4.37e-06	7.98e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KIT—muscle cancer	4.32e-06	7.91e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—KIT—muscle cancer	4.27e-06	7.81e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—PTGS2—muscle cancer	4.27e-06	7.8e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IGF2—muscle cancer	4.27e-06	7.8e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ENO2—muscle cancer	4.22e-06	7.72e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FOXO1—muscle cancer	4.2e-06	7.68e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—MDM2—muscle cancer	4.2e-06	7.68e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—MDM2—muscle cancer	4.19e-06	7.66e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MED12—muscle cancer	4.13e-06	7.56e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MDM2—muscle cancer	4.1e-06	7.5e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	4.1e-06	7.5e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—MDM2—muscle cancer	4.09e-06	7.48e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PTGS2—muscle cancer	4.05e-06	7.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PTGS2—muscle cancer	4.04e-06	7.39e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MED12—muscle cancer	4.03e-06	7.38e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MDM2—muscle cancer	4e-06	7.31e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TP53—muscle cancer	3.99e-06	7.29e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KIT—muscle cancer	3.94e-06	7.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FOXO1—muscle cancer	3.93e-06	7.18e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TP53—muscle cancer	3.83e-06	7e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MED12—muscle cancer	3.8e-06	6.95e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MDM2—muscle cancer	3.78e-06	6.9e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MED12—muscle cancer	3.77e-06	6.89e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ENO2—muscle cancer	3.77e-06	6.89e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KIT—muscle cancer	3.74e-06	6.83e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KIT—muscle cancer	3.73e-06	6.81e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IGF2—muscle cancer	3.68e-06	6.73e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ENO2—muscle cancer	3.68e-06	6.72e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—MDM2—muscle cancer	3.64e-06	6.66e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PTGS2—muscle cancer	3.64e-06	6.65e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ENO2—muscle cancer	3.47e-06	6.34e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—muscle cancer	3.45e-06	6.3e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MDM2—muscle cancer	3.44e-06	6.29e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ENO2—muscle cancer	3.44e-06	6.28e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MDM2—muscle cancer	3.41e-06	6.23e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FOXO1—muscle cancer	3.39e-06	6.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MDM2—muscle cancer	3.36e-06	6.15e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KIT—muscle cancer	3.36e-06	6.14e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.3e-06	6.04e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTGS2—muscle cancer	3.24e-06	5.93e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MED12—muscle cancer	3.22e-06	5.89e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KIT—muscle cancer	3.2e-06	5.85e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—VEGFA—muscle cancer	3.12e-06	5.7e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MDM2—muscle cancer	3.1e-06	5.67e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MDM2—muscle cancer	3.1e-06	5.67e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—VEGFA—muscle cancer	3.04e-06	5.55e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KIT—muscle cancer	2.99e-06	5.47e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.95e-06	5.39e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MDM2—muscle cancer	2.94e-06	5.38e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ENO2—muscle cancer	2.94e-06	5.37e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MDM2—muscle cancer	2.93e-06	5.37e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTGS2—muscle cancer	2.79e-06	5.11e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTGS2—muscle cancer	2.79e-06	5.11e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.69e-06	4.91e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MDM2—muscle cancer	2.64e-06	4.83e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VEGFA—muscle cancer	2.61e-06	4.77e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VEGFA—muscle cancer	2.59e-06	4.73e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KIT—muscle cancer	2.58e-06	4.72e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MDM2—muscle cancer	2.52e-06	4.61e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MED12—muscle cancer	2.49e-06	4.54e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—muscle cancer	2.37e-06	4.33e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MDM2—muscle cancer	2.36e-06	4.31e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—muscle cancer	2.35e-06	4.3e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—muscle cancer	2.35e-06	4.3e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—muscle cancer	2.35e-06	4.3e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—muscle cancer	2.35e-06	4.29e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.3e-06	4.2e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—muscle cancer	2.29e-06	4.19e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ENO2—muscle cancer	2.27e-06	4.14e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—muscle cancer	2.23e-06	4.08e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—muscle cancer	2.23e-06	4.07e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MDM2—muscle cancer	2.03e-06	3.72e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—muscle cancer	2.01e-06	3.67e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—muscle cancer	1.97e-06	3.61e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—muscle cancer	1.95e-06	3.57e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—muscle cancer	1.91e-06	3.5e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—muscle cancer	1.79e-06	3.27e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—muscle cancer	1.78e-06	3.25e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—muscle cancer	1.78e-06	3.25e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—muscle cancer	1.74e-06	3.18e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—muscle cancer	1.7e-06	3.1e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—muscle cancer	1.69e-06	3.09e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—muscle cancer	1.68e-06	3.08e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—muscle cancer	1.54e-06	2.82e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—muscle cancer	1.52e-06	2.77e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—muscle cancer	1.47e-06	2.69e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—muscle cancer	1.45e-06	2.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—muscle cancer	1.35e-06	2.47e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—muscle cancer	1.31e-06	2.4e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—muscle cancer	1.28e-06	2.34e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—muscle cancer	1.21e-06	2.21e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—muscle cancer	1.2e-06	2.19e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—muscle cancer	1.17e-06	2.13e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—muscle cancer	1.02e-06	1.87e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—muscle cancer	7.89e-07	1.44e-05	CbGpPWpGaD
